"目录号: HY-14286
Levosimendan(OR1259)是钙增敏剂，通过与cardiac troponin C (cTnC)结合而发挥作用。
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3].
Clinical Trial
Hospital Universitario de Canarias-Orion Corporation, Orion Pharma
Ventricular Dysfunction, Left-Hip Fracture
May 2014
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Mitral Valve Stenosis With Incompetence or Regurgitation
July 2009
Phase 4
Bambino Gesù Hospital and Research Institute
Low Cardiac Output Syndrome
January 2009
Phase 2
Hospital Universitario de Canarias
Advanced Heart Failure
November 2009
Phase 4
AHEPA University Hospital-Orion Corporation, Orion Pharma
Coronary Artery Disease
March 2011
Phase 4
RWTH Aachen University
Myocardial Infarction-Outcome
June 2017
VieCuri Medical Centre-Orion Corporation, Orion Pharma
Acute Kidney Injury
September 2016
Phase 2-Phase 3
Medical University Innsbruck-Orion Corporation, Orion Pharma
Chronic Stable Heart Failure
August 2009
Phase 3
Sahlgrenska University Hospital, Sweden
Acute Kidney Injury-Renal Insufficiency, Acute
September 2015
Phase 4
Parc de Salut Mar
Heart Failure
April 2010
Phase 4
Ullevaal University Hospital
Heart Failure-Cardiac Surgery
January 2003
University Medical Center Nijmegen-Orion Corporation, Orion Pharma
Muscle Weakness Conditions-Weaning Failure
September 2012
Phase 2-Phase 3
Niguarda Hospital-Orion Corporation, Orion Pharma
Advanced Chronic Heart Failure
February 2011
Phase 3
Tampere University Hospital
Heart Valve Disease
January 2009
Phase 4
Kuopio University Hospital
Heart Failure
March 2005
Phase 4
Sahlgrenska University Hospital, Sweden
Septic Shock-Cardiomyopathy
December 2015
Phase 4
Jose Luis Vazquez Martinez-Hospital Universitario Ramon y Cajal
Acute Heart Failure
February 2011
Phase 2
Göteborg University-Sahlgrenska University Hospital, Sweden
Cardiorenal Syndrome
April 2014
Phase 3
Università Vita-Salute San Raffaele
Low Cardiac Output Syndrome
November 2009
Phase 4
Tenax Therapeutics, Inc.
Coronary Artery Bypass Grafting-Mitral Valve Surgery-Low Cardiac Output Syndrome
July 2014
Phase 3
University of Aarhus
Diastolic Dysfunction-Left Ventricular Hypertrophy
September 2010
Phase 4
University of Roma La Sapienza
Septic Shock
November 2007
Phase 2
Centro Cardiologico Monzino-Orion Corporation, Orion Pharma
Heart Failure
September 2012
Phase 4
Sykehuset i Vestfold HF-Orion Corporation, Orion Pharma
Heart Failure-Hip Fracture
April 2011
Phase 4
Assistance Publique - Hôpitaux de Paris-Ministry of Health, France
Coronary Artery Bypass Grafting-Left Ventricular Dysfonction
June 2013
Phase 3
University Medical Center Nijmegen-Orion Corporation, Orion Pharma
Respiratory Muscle Function
April 2010
Orion Corporation, Orion Pharma
Coronary Heart Disease
January 2004
Phase 2
Tenax Therapeutics, Inc.
Heart Decompensation
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cardiac Surgery
February 2011
Phase 4
Göteborg University-Helsinki University Central Hospital
Congenital Heart Defects
October 2014
Phase 2
Tampere University Hospital
Myocardial Stunning
January 2012
Phase 4
Military Hospital of Tunis
Septic Shock
January 2011
Orion Corporation, Orion Pharma
Chronic Heart Failure-Heart Diseases
March 2005
Phase 2
University of Utah
Heart Failure
September 2006
Phase 2
Oslo University Hospital
Myocardial Infarction-Heart Failure-Cardiogenic Shock
June 2006
Phase 4
Orion Corporation, Orion Pharma
Transient Ischemic Attack-Stroke
August 2008
Phase 2
Emory University-Abbott
Heart Failure
May 2005
Phase 3
University of Roma La Sapienza-University College London Hospitals
Myocardial Protection
January 2005
Phase 4
Abbott-Orion Corporation, Orion Pharma
Heart Failure, Congestive
September 2002
Phase 3
Azienda Policlinico Umberto I
Cardiovascular Diseases
December 2013
Phase 4
University of Roma La Sapienza
Heart Failure-Renal Insufficiency
October 2007
Phase 4
Wentworth Area Health Services-Abbott
Cardiogenic Shock-Septic Shock
October 2004
Phase 2-Phase 3
Ludwig Boltzmann Gesellschaft
Low Cardiac Output Syndrome
September 2007
Phase 2
Charite University, Berlin, Germany
Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery
January 2006
Abbott-Orion Corporation, Orion Pharma
Acute Heart Failure
March 2003
Phase 3
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Congenital Cardiovascular Defects-Low Cardiac Output Syndrome
July 2008
Qilu Hospital of Shandong University
Early Management-Acute Heart Failure-NSTEMI - Non-ST Segment Elevation MI
July 1, 2017
Phase 4
Federal University of Juiz de Fora-Universidade Federal do Rio de Janeiro-National Institute of Cardiology/Ministry of Health
Cardiopulmonary Bypass Graft
February 2012
Phase 4
